ReviewInternational journal of molecular sciences2019
Advances in Understanding the Immunological Pathways in Psoriasis.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 149 citations in OpenAlex.
- Keratinocytes as active regulators of cutaneous and mucosal immunity: a systematic review across inflammatory epithelial disorders.Frontiers in immunology · 2025Pooled it
- System Pharmacology-Based Anti-proliferation and Anti-angiogenesis Mechanisms of Oridonin in Psoriasis Keratinocytes by Blocking PI3K/AKT Signaling Pathway.Chinese journal of integrative medicine · 2026Article
- Skin Microbiome in Health and Disease: Dysbiosis and the Emerging Role of Biotics in Therapy and Protection.International journal of molecular sciences · 2026Review
- Pilot validation of the genital psoriasis reported outcomes questionnaire in an Italian cohort.Frontiers in medicine · 2026Article
- Psoriasis, stem cells, and obesity: metabolic exploration for therapeutics.Journal of medicine and life · 2025Review
- Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis.Journal of advanced research · 2025Review
- Comparative Efficacy of Ustekinumab and Guselkumab in Improving Itch in Severe Psoriasis Patients.Annals of dermatology · 2025Article
- Atorvastatin attenuates the expression of damage-associated molecular patterns and inflammatory cytokines in patients with psoriasis.Pharmacological reports : PR · 2025Article
- Immunological Antagonism Between Psoriasis and Atopic Dermatitis: Pathways, Clinical Implications, and Therapeutic Perspectives.Clinical, cosmetic and investigational dermatology · 2025Review
- Psoriasis: Unraveling Disease Mechanisms and Advancing Pharmacological and Nanotechnological Treatments.Journal of inflammation research · 2025Review
- Editorial: Autoimmunity: novel insights and future perspectives.Frontiers in immunology · 2025Article
- Electrostimulation: A Promising New Treatment for Psoriasis.International journal of molecular sciences · 2024Review
- Exposure to Per- and Polyfluoroalkyl Substances and Risk of Psoriasis: A Population-Based Study.Toxics · 2024Article
- Epidermal Barrier Parameters in Psoriasis: Implications in Assessing Disease Severity.Journal of personalized medicine · 2024Article
- Article
- Inflammatory Skin Diseases: Focus on the Role of Suppressors of Cytokine Signaling (SOCS) Proteins.Cells · 2024Review
- Psoriasis: What Is New in Markers of Disease Severity?Medicina (Kaunas, Lithuania) · 2024Review
- The Influence of Phytoconstituents for the Management of Antipsoriatic Activity in Various Animal Models.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2024Review
- Experiences of Dermatologists and Patients Regarding Psoriasis and Its Connection to Psoriatic Arthritis in Saudi Arabia.Psoriasis (Auckland, N.Z.) · 2024Article
- Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis.Dermatology and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Psoriasis vulgaris is a chronic, immune-mediated, inflammatory, polygenic skin disorder affecting approximately 2% of the population. It has a great impact on quality of life; patients often experience depression, anxiety, stigma as well as suicidal behavior. Even though psoriasis is one of the most studied dermatological conditions, the pathogenesis of the disease is still not completely elucidated. The complex interactions between keratinocytes, dendritic cells, T-lymphocytes, neutrophils and mast cells are responsible for the histopathological changes seen in psoriasis. The pathogenic model leading to the formation of psoriatic plaques has however evolved a lot over the years. There is now enough evidence to support the role of interleukin (IL) -23, IL-17, IL-22, T helper (Th) -17 cells, Th-22 cells, T regulatory cells, transforming growth factor (TGF)-β1 and IL-10 in the pathogenesis of the disease. Moreover, several inflammatory and anti-inflammatory molecules are currently being investigated, some of them showing promising results. The aim of this paper is to look over the most recent advances in the immunological pathways involved in the pathogenesis of psoriasis vulgaris.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.